Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • Posters & Publications
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 27, 2017 7:35am EDT

Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501

Mar 10, 2017 8:05am EST

Matinas BioPharma to Present at 29th Annual ROTH Conference

Mar 08, 2017 8:01am EST

Matinas BioPharma Announces Positive Preclinical Efficacy Results of MAT2501 in an In Vitro Model of Mycobacterium abscessus Infection

Mar 06, 2017 8:05am EST

Matinas BioPharma and NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in Chronic Mucocutaneous Candidiasis

Feb 27, 2017 8:30am EST

Matinas BioPharma Announces Trading on NYSE MKT to Commence March 2, 2017

Jan 26, 2017 7:00am EST

Matinas BioPharma Provides Business Outlook and Sets Corporate Milestones for 2017

Jan 23, 2017 7:05am EST

Matinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference

Jan 19, 2017 7:05am EST

Matinas BioPharma Successfully Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants

Jan 06, 2017 7:35am EST

Matinas BioPharma to Present at Biotech Showcase™ 2017

Dec 08, 2016 7:05am EST

Matinas BioPharma Receives Contract Award from Cystic Fibrosis Foundation Therapeutics to Study MAT2501 for the Treatment of NTM-Infection in Pre-Clinical Models of CF

RSS
  • Prev
    • 1...
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • ...28
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LNC PLATFORM
    • MAT2203
    • Posters & Publications

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2025 Matinas BioPharma Holdings, Inc. All Rights Reserved.